In What Scenarios Does a Mobile Stroke Unit Predict Better Patient Outcomes?: A Modeling Study.


Journal

Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266

Informations de publication

Date de publication:
06 2020
Historique:
pubmed: 12 5 2020
medline: 15 9 2020
entrez: 12 5 2020
Statut: ppublish

Résumé

Background and Purpose- The mobile stroke unit (MSU) brings imaging and thrombolysis to patients in the field. The MSU has the potential to decrease time from onset to thrombolysis; however, this depends on the location of the patient, the MSU, and the hospital. The MSU will only be able to treat a small subset of patients it is dispatched to. Using conditional probability modeling, we evaluate in which scenarios the MSU exhibits clear benefit over the direct-to-mothership method. Methods- Previously published conditional probability models for drip-and-ship versus mothership transport were modified to reflect MSU workflow. It was assumed that the MSU was dispatched from the endovascular therapy center. Eight scenarios were generated, varying treatment efficiency on the MSU and at the endovascular therapy center and the threshold for dispatching the MSU (low threshold: low treatment rate but few missed patients; high threshold: higher treatment rate, potential for missed treatment opportunities). Results- The relative difference in outcomes between the MSU and mothership was small. Geographic areas where the MSU is superior to mothership increase in size as treatment time on the MSU decreases. When a high-threshold dispatch system is used, the area where the MSU is superior decreases, but the relative difference in predicted outcomes between the MSU and mothership increases. The largest relative difference favoring the MSU was found in areas where the patient would forgo access to alteplase, based upon a 4.5-hour treatment threshold, using mothership transport. Conclusions- There are few scenarios where MSU transport predicts substantially superior outcomes to the mothership method when the MSU is dispatched from the endovascular therapy center. Outcomes using the MSU are maximized when dispatch criteria that maximize patients eligible for thrombolysis treatment are used and treatment times on the MSU are short relative to those of the endovascular therapy center.

Identifiants

pubmed: 32389068
doi: 10.1161/STROKEAHA.119.028474
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1805-1812

Commentaires et corrections

Type : CommentIn

Auteurs

Jessalyn K Holodinsky (JK)

From the Evaluative Clinical Sciences Platform, Sunnybrook Research Institute, Toronto, ON, Canada (J.K.H.).

Noreen Kamal (N)

Department of Industrial Engineering, Dalhousie University, Halifax, Nova Scotia, Canada (N.K.).

Charlotte Zerna (C)

Department of Community Health Sciences (C.Z., M.D.H.), University of Calgary, Alberta, Canada.
Department of Clinical Neurosciences, Cumming School of Medicine (C.Z., J.M.O., A.T.W., M.D.H., M.G.), University of Calgary, Alberta, Canada.
Hotchkiss Brain Institute, Cumming School of Medicine (C.Z., A.T.W., M.D.H., M.G.), University of Calgary, Alberta, Canada.

Johanna M Ospel (JM)

Department of Clinical Neurosciences, Cumming School of Medicine (C.Z., J.M.O., A.T.W., M.D.H., M.G.), University of Calgary, Alberta, Canada.
Department of Radiology, University Hospital Basel, University of Basel, Switzerland (J.M.O.).

Luke Zhu (L)

Department of Bioengineering, University of Washington, Seattle (L.Z.).

Alexis T Wilson (AT)

Department of Clinical Neurosciences, Cumming School of Medicine (C.Z., J.M.O., A.T.W., M.D.H., M.G.), University of Calgary, Alberta, Canada.
Hotchkiss Brain Institute, Cumming School of Medicine (C.Z., A.T.W., M.D.H., M.G.), University of Calgary, Alberta, Canada.

Michael D Hill (MD)

Department of Community Health Sciences (C.Z., M.D.H.), University of Calgary, Alberta, Canada.
Department of Clinical Neurosciences, Cumming School of Medicine (C.Z., J.M.O., A.T.W., M.D.H., M.G.), University of Calgary, Alberta, Canada.
Hotchkiss Brain Institute, Cumming School of Medicine (C.Z., A.T.W., M.D.H., M.G.), University of Calgary, Alberta, Canada.
Calgary Stroke Program, Cumming School of Medicine (M.D.H.), University of Calgary, Alberta, Canada.
Department of Medicine, Cumming School of Medicine (M.D.H.), University of Calgary, Alberta, Canada.

Mayank Goyal (M)

Department of Clinical Neurosciences, Cumming School of Medicine (C.Z., J.M.O., A.T.W., M.D.H., M.G.), University of Calgary, Alberta, Canada.
Hotchkiss Brain Institute, Cumming School of Medicine (C.Z., A.T.W., M.D.H., M.G.), University of Calgary, Alberta, Canada.
Department of Radiology, Cumming School of Medicine (M.G.), University of Calgary, Alberta, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH